Comparison of brimonidine/latanoprost and timolol/dorzolamide: Two randomized, double-masked, parallel clinical trials

Advances in Therapy

Volumn 20, Issue 2, 2003, Pages 92-100

  Zabriskie, Norman ^a   Netland, Peter A ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Brimonidine; Dorzolamide; Fixed combination; Latanoprost; Timolol

Indexed keywords

BRIMONIDINE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST;

ADULT; AGED; ALLERGY; ANOREXIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0038208100     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850256     Document Type: Article

References (16)

1. Kobelt G. Comparative data for all countries. In: Jonsson B, Kriegelstein G, eds. Primary Open-Angle Glaucoma. Differences in International Treatment Patterns and Costs. Oxford, England: ISIS Medical Media; 1998:116-126.
2. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamidetimolol combination versus the concomitant administration of its components. Ophthalmology. 1998;105:1936-1944.
3. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999;127:20-26.
4. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin Ther. 2000;22:103-111.
5. Lee DA, Gornbein J. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated IOP in a large, open-label community trial. J Glaucoma. 2001;10:220-226.
6. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109:307-315.
7. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther. 2001;23:604-620.
8. Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin Ther. 2000;22:388-399.
9. Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post-hoc analysis of an open-label community trial. J Ocul Pharmacol Ther. 2000;16:3-18.
10. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom, and the United States. Surv Ophthalmol. 1997;41(suppl 2):S105-S110.
11. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
12. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
13. Martin L. Clinical experience with latanoprost: a retrospective study of 153 patients. Acta Ophthalmol Scand. 1999;77:336-339.
14. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
15. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497. Published erratum appears in Am J Ophthalmol. 1999;127:120.
16. Walters TR, Shapiro A, Mroz M. A comparison of the efficacy and tolerability of brimonidine/latanoprost versus timolol/latanoprost dual therapy. Invest Ophthalmol Vis Sci. 2000;41:S514. Abstract 2736.